PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031

	U. S. Patent and Trader	mark Office; U.S. DEPARTMENT OF COMMERCE
	Application Number	10/690,118
	Filing Date	October 21, 2003
	First Named Inventor	Albaneze-Walker, et al
	Art Unit	1625
	Examiner Name	B. Dentz
22	Attorney Docket Number	21229Y-2
	22	Application Number Filing Date First Named Inventor Art Unit Examiner Name

ENCLOSURES (Check all that apply) Fee Transmittal Form	Total Number of Pages in This Submission		22	Attorney Docket Numbe		29Y-2		
Fee Transmittal Form Fee Attached Drawing(s) After Allowance Community To Technology Center (TC Appeal Communication to of Appeals and Interference Petition After Final Petition to Convert to a Appeal Communication to of Appeals and Interference Provisional Application Appeal Communication to (Appeal Notice, Brief, Repty Proprietary Information Proprietary Information Proprietary Information Change of Correspondence Address Status Letter Request for Refund Change of Correspondence Address Proprietary Information Change of Correspondence Address Status Letter Change of Correspondence Address Request for Refund Change of Correspondence Address Request for Refund Change of Correspondence Cha	Tom Tumor of Tugos in Tims Suchlission							<u> </u>
Name Curtis C. Panzer Registration No. (Attorney/Agent) 33,752 Signature Date 6/29/2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United St Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents,	Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Petition Petition to Provision Power of Change of Change of Change of Change of Request for CD, Num		g-relate to Conv nal App f Attorn of Corre	d Papers ert to a lication ey, Revocation espondence Address imer		to Tec Appea of App Appea (Appea Propri Status Other	hnology Center (TC) Il Communication to Boseals and Interferences Il Communication to To al Notice, Brief, Reply Betary Information Letter Enclosure(s) (please	oard
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United St Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents,	SIGNATU	RE OF APP	LICAN	T, ATTORNEY, O	R AGI	ENT		
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United St Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents,				Registration No. (Attorney/Agent)			33,752	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United St Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents,	ignature			<u>. </u>		Date	6/29/2004	
P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: 29 June 2004 Typed or printed Curtis C. Panzer Signature Date June 29, 2004	I hereby certify that this correspondence Postal Service with sufficient postage as P.O. Box 1450, Alexandria, Virginia 223 Typed or printed Curtis C. Panzer	is being facsin first class mai	mile tra	nsmitted to the USPT envelope addressed to 29 June 2004	O or do: Con	nmissio	oner for Patents,	:s

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



In re application of: ALBANEZE-WALKER, ET AL	
Serial No. 10/690,118	
Filed October 21, 2003	
Group Art Unit 1625	
Examiner B. Dentz	

For: ONE POT METHOD OF PREAPRING INTERMEDIATES USEFUL IN MAKING OF PHOSPHODIESTERASE-4

Transmitted herewith is	in amendment in	the above-identified	application.
-------------------------	-----------------	----------------------	--------------

\mathbf{X}	No	additional	fee	is	required.
--------------	----	------------	-----	----	-----------

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims remaining after amendment		Highest Number Previously Paid For	Present Extra	Rate	Additional Fee
Total Claims	*	-	** =	0 X	\$18	=0.00
Independent Claims	*	-	***=	X	\$86	=0.00
Multiple Dependent Claims					\$290 ****	=
		<u>† </u>	TOTAL ADDITIONAL FEE FOR THIS AMENDMENT			

- * If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.
- ** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.

 *** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.
- Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ <u>0.00</u>	to Deposit Account No.	13-2755. Please c	harge any additional	fees or credit
overpayment to Deposit Ac	count No. 13-2755. A d	luplicate copy of thi	s sheet is enclosed.	

Respectfully, Cany
By: Curtis C. Panzer \int
Attorney for Applicant(s)
Reg. No. <u>33,752</u>
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732) 594- <u>3199</u>
Date: June 29, 2004

IN DUPLICATE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Albaneze-Walker et al.

Serial No.:

10/690,118

Case 21229Y-2

Art Unit: 1625

Filed

October 21, 2003

. Examiner: B. Dentz

For

One Pot Method of Preparing intermediates Useful in

Making Inhibitors of Phosphodiesterase-4

Assistant Commissioner for Patents Washington, D.C. 20231

AMENDMENT

This is in response to a non-final Office Action Mailed April 14, 2004, setting forth a shortened statutory period for response ending July 14, 2004. Reconsideration of Applicants claims is requested. Any additional fees required in connection with this amendment may be taken from Merck deposit Account 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.